Low prevalence of gingival overgrowth associated to new imunossupressive protocols with cyclosporin (original) (raw)
Related papers
Journal (Canadian Dental Association), 2003
This investigation was performed to evaluate the effect of cyclosporine alone and in combination with nifedipine on gingival overgrowth. One hundred and nineteen patients who had undergone renal transplantation at least 12 months previously were selected for the study. The patients were divided into 2 groups according to whether they had received cyclosporine alone (group 1, n = 98) or cyclosporine with nifedipine (group 2, n = 21). Periodontal and pharmacological characteristics were assessed for all patients. Marked gingival overgrowth was seen in 11 (52%) of the patients in group 2 but just 6 (6%) of those in group 1. In addition, the gingival overgrowth index was significantly greater for patients who had received both nifedipine and cyclosporine (Mann-Whitney U-test, p < 0.001). However, there were no significant differences between groups with higher and lower gingival overgrowth index in terms of age, sex, cyclosporine dose, nifedipine dose or level of cyclosporine in the ...
Materia Socio-Medica, 2021
Background: Cyclosporine A (CsA) is a potent immunosuppressant widely used to prevent renal post transplantation rejection. Gingival overgrowth (GO) is among various side effects of the long-term administration of CsA. Up to 90% of the patients under CsA therapy has been reported to develop CsA-induced GO. Objectives: The aim of the present prospective pilot study is to determine the local and systemic effects of Cyclosporine A (CsA) on the severity of gingival overgrowth and its relationship with periodontal parameters in post-transplant renal patients Methods: Twenty post-transplant renal patients, 12 females and 8 males, presenting gingival overgrowth were selected from Rizk Hospital’s clinic in Beirut. Patient’s CsA plaque levels were evaluated when CsA is administered by syrup and capsules mode. Periodontal parameters including gingival overgrowth, papillary bleeding, plaque and gingival indices were assessed for all patients. Results: Plaque concentration CsA levels, when admi...
Gingival enlargement and its risk factors in kidney transplant patients receiving cyclosporine A
Iranian journal of kidney diseases, 2010
Gingival enlargement is one of the most cumbersome complications of cyclosporine A. It affects patient's life style by impairing the appearance and function of masticatory tract. This study was conducted on a sample of Iranian kidney transplant recipients to determine the frequency and risk factors of cyclosporine-induced gingival enlargement. A total of 200 kidney transplant recipients (mean age, 39.7 +/- 13.2 years) were enrolled in this study. All of the participants were receiving cyclosporine for at least 12 months prior to the study. Factors including age, gender, cyclosporine dose, serum concentration of cyclosporine, duration of immunosuppressive administration, plaque, and gingival indexes were evaluated. Seventy kidney transplant recipients (35%) showed various degrees of gingival enlargement. Serum cyclosporine concentration and the intensity of gingival enlargement (McGraw index) had a significant correlation (r = 0.35, P < .001). Multiple regression analysis reve...
Update on gingival overgrowth by cyclosporine A in renal transplants
Medicina oral, patología oral y cirugía bucal, 2007
Severe gingival overgrowth is one of the most frequent side effects in renal transplant patients associated with assumption of cyclosporine A. Several associations with age, sex, dosage, duration of therapy or interval since transplantation have been hypothesized. The introduction of alternative immunosuppressant drugs have been suggested to permit better long-term transplant outcomes and a decrease in incidence of gingival overgrowth. The aim of the present paper is to summarize current knowledge regarding aetiology, pathogenesis and management of gingival overgrowth induced by Cyclosporine A.
Cyclosporine-A Induced Gingival Overgrowth
2006
Background. The link between the gingival overgrowth and cyclosporine pharmacokinetical variables, especially cyclosporine doses which appear to act as stimulator of the gingival proliferative changes, presents a field of interest of large number of researches. The existence of undefined association and/or interaction between the cyclosporine and periodontal variables, could be responsible for this type of gingival overgrowth. The aim of this study was to examine the correlation between the degree of gingival overgrowth, daily doses of cyclosporine A and parodontal parameters. Methods. 120 patients with renal transplants were included in this examination. The cohort was divided into a four groups according to the daily dose of cyclosporine (100, 125, 150, 175 mg). The degree of gingival overgrowth (GOI) was investigated, using a MacGaw index. The plaque index (PI), apical migration, total daily doses of cyclosporine and plasma concentration, was recorded for various groups and a pro...
Gingival overgrowth induced by nifedipine and cyclosporin
Journal of Clinical …, 1995
Abstract. In this study, we developed a quantitative method with digital image analysis to evaluate the degree of gingival overgrowth (GO), and compared GO in kidney transplant patients treated with cyclosporin A (CsA)(n= 21) or CsA+ nifedipine (n= 8) and a group of ...
Journal of Periodontology, 1992
The aim of this study was to determine the occurrence of gingival overgrowth (GO) among renal transplant recipients and to analyze possible background factors causing GO among cyclosporine-treated (CsA) patients as compared with others receiving azathioprine (Aza). A total of 32 recipients, 22 treated with CsA and 10 with Aza (ages 22 to 68 years) participated. The examination included determination of renal function, whole blood CsA concentration, and periodontal status. The tooth surface data were analyzed in terms of the given background variables for GO in the whole patient sample by logistic regression analysis. The occurrence of GO was significantly higher in the CsA group as compared with the Aza group (P <0.03). The CsA responders had significantly more gingival units overgrown as compared with the Aza responders (P < 0.005). There were no differences in age, sex, whole blood concentration of CsA, or duration of CsA medication between the responders and non-responders. Expressed as individual means, the gingival inflammation scores were significantly higher among the CsA responders than among the CsA non-responders (P < 0.005). Analysis of the surface data showed that CsA had an independent major effect on GO. Furthermore, simultaneous gingival bleeding increased the risk of overgrowth (odds ratio = 2). The results show that CsA medication is a significant factor for GO and the risk of the occurrence of GO is further increased by simultaneous gingival inflammation.
Journal of Clinical Periodontology, 2010
Aim: To assess the prevalence and variables associated with gingival overgrowth (GO) in renal transplant recipients medicated with cyclosporine (CsA), tacrolimus (Tcr), or sirolimus (Sir). Materials and Methods: One hundred and thirty-five eligible subjects were divided in CsA, Tcr, and Sir groups comprising 45 subjects each. GO was visually assessed and subjects were assigned as GO1 or GO À in a post hoc definition. Saliva samples were collected and the presence of periodontal pathogens was assessed through polymerase chain reaction. Variables of interest were compared between GO1 and GO À subjects through univariate and multivariate analysis. Results: Prevalence of GO was of 60.0% for CsA, 28.9% for Tcr, and 15.6% for Sir groups. Within the CsA group, GO was associated with papillary bleeding index (p 5 0.001); within the Tcr group, GO was associated with CsA previous use (p 5 0.013), and calcium channel blockers (CCB) use (p 5 0.003); within the Sir group, GO was associated with papillary bleeding index (p 5 0.018), and CCB use (p 5 0.020). A higher frequency of Tannerella forsythia was observed among GO1 subjects medicated with Tcr. Conclusion: Pharmacological and periodontal variables were associated with GO in different immunosuppressive regimens. Integration between the medical and the dental team may be an important approach in the post-transplant maintenance routine.
Gingival overgrowth among renal transplant recipients and uraemic patients
Nephrology Dialysis Transplantation, 1993
The aim of this study was to determine the occurrence of gingival overgrowth (GO) among renal transplant recipients and to analyze possible background factors causing GO among cyclosporine-treated (CsA) patients as compared with others receiving azathioprine (Aza). A total of 32 recipients, 22 treated with CsA and 10 with Aza (ages 22 to 68 years) participated. The examination included determination of renal function, whole blood CsA concentration, and periodontal status. The tooth surface data were analyzed in terms of the given background variables for GO in the whole patient sample by logistic regression analysis. The occurrence of GO was significantly higher in the CsA group as compared with the Aza group (P <0.03). The CsA responders had significantly more gingival units overgrown as compared with the Aza responders (P < 0.005). There were no differences in age, sex, whole blood concentration of CsA, or duration of CsA medication between the responders and non-responders. Expressed as individual means, the gingival inflammation scores were significantly higher among the CsA responders than among the CsA non-responders (P < 0.005). Analysis of the surface data showed that CsA had an independent major effect on GO. Furthermore, simultaneous gingival bleeding increased the risk of overgrowth (odds ratio = 2). The results show that CsA medication is a significant factor for GO and the risk of the occurrence of GO is further increased by simultaneous gingival inflammation.